A counteracting agent may be the stable gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, MW 1419, an anti-ulcer peptide per-orally active (12-15) that may also affect many central disturbances (16-23), efficient in inflammatory bowel disease trials (PL 14736) (24, 25) and various wound treatment (26-28), no toxicity reported (12, 13, 24, 25)) which showed various hepatoprotective effects (29-31)
Slows cellular aging, helps to strengthen bones, and prevents age-related cognitive decline
Ozempics manufacturer, Novo Nordisk, has not objected to the application to consolidate cases, so we believe an MDL is likely
Gastroenterology 2008 Reported that the tripeptide KPV was taken up via PepT1 and reduced markers of inflammation in cell and mouse models